In the fourth blog in our series looking at the story behind the
EFPIA Manifesto, Sini Eskola, Director of Regulatory, Drug Development and Manufacturing at EFPIA looks at the case for fast-tracking advanced therapies for patients across Europe.
Our vision is to improve Europe’s capability to fast-track breakthrough therapies which meet the unmet medical needs of patients. Key to realising that ambition is ensuring that the European Medicines Agency (EMA) has the resources and flexibility to be at the forefront of regulatory excellence globally. This is even more critical in the context of the challenges presented by the Agency’s relocation as a result of
Brexit.
